Pulmonary Fibrosis News Home | Pulmonary Fibrosis News
WEBPhase 2b trial tests AP01, inhaled pirfenidone, in progressive PF. Avalyn Pharma has started a Phase 2b clinical trial testing the safety and efficacy of AP01, its investigational inhaled formulation of pirfenidone, in adults with progressive pulmonary fibrosis (PF).
New prototype therapy may repair IPF lung scarring by …
WEBApr 26, 2024 · Researchers have developed an inhalable prototype medicine that may be able to repair lung scarring caused by idiopathic pulmonary fibrosis (IPF) by stimulating the growth of stem cells directly in the lungs, a study reports.
IPF Update: FIBRONEER-IPF Study of Nerandomilast Meets …
WEB6 days ago · The FIBRONEER-IPF trial included 1177 participants with IPF across more than 30 countries. They were divided into 3 groups, taking a dose of nerandomilast 9 mg, nerandomilast 18 mg, or placebo twice daily. The primary end point was absolute change in FVC from baseline to week 52. 1. After 52 weeks, patients taking either dose of nerandomilast ...
BMS-986278 declared breakthrough therapy for progressive PF
WEBOct 27, 2023 · The FDA’s decision to grant breakthrough therapy designation to BMS-986278 was based on results from a global Phase 2 clinical trial (NCT04308681) assessing the safety and efficacy of BMS-986278 in 278 people with …
Study reveals potential to reverse lung fibrosis using the body's …
WEBApr 12, 2024 · Researchers are urgently trying to find ways to prevent or slow idiopathic pulmonary fibrosis (IPF) and related lung conditions, which can cause worsening shortness of breath, dry cough, and...
Yale researchers discover new approach to reversing lung scarring
WEBFeb 10, 2023 · Yale researchers have identified a potential treatment for idiopathic pulmonary fibrosis, or IPF, which can reverse lung scarring.
IPF Mortality Predicted by 6-Minute Walk Test Oxygen Desaturation
WEB16 hours ago · Patients with IPF whose 6-minute walk test distance declined by 50 meters or more in a 12-month period had shorter survival times than other patients with IPF. Desaturation during the 6-minute walk test (6MWT) is a significant predictive factor for mortality in patients with idiopathic pulmonary fibrosis (IPF), according to study findings in ...
Newly Designed Molecule Is Promising Potential Therapy for …
WEBOct 28, 2022 · A team led by Kaminski used a newly designed molecule, called MRG-229, with potential therapeutic implications for IPF. The study is one of the first to use a microRNA mimic as a viable therapeutic in the lungs. The group published its findings October 17 in eBioMedicine.
Experimental anticancer drug shows promise as treatment for …
WEBAug 23, 2022 · An experimental anticancer drug called saracatinib shows promise as a treatment for Idiopathic Pulmonary Fibrosis (IPF), a chronic and often fatal condition that causes scarring or fibrosis of the lungs and makes breathing difficult.
Zinc may reverse lung damage, improve survival for patients with ...
WEBJun 8, 2022 · Idiopathic pulmonary fibrosis, or IPF, affects 100,000 people in the U.S. and has no known cause. The condition, which leads to scarring of the lungs, called fibrosis, and progressive...
- Some results have been removed
Skip to content